How should synchronized electrical cardioversion be performed in a hemodynamically stable patient with symptomatic rapid atrial fibrillation or flutter, including anticoagulation, sedation, energy settings, and post‑procedure monitoring?

Synchronized Electrical Cardioversion for Symptomatic Atrial Fibrillation/Flutter

For hemodynamically stable patients with symptomatic rapid atrial fibrillation or flutter, perform synchronized electrical cardioversion using biphasic waveform at 200 J initial energy in anteroposterior pad position, with mandatory anticoagulation for ≥3 weeks before (or TEE-guided approach) and ≥4 weeks after the procedure, under adequate procedural sedation to ensure amnesia.

Anticoagulation Strategy

The anticoagulation approach depends critically on arrhythmia duration:

For AF/Flutter Duration <48 Hours

• Immediate cardioversion is permissible without prolonged anticoagulation 1, 2
• However, initiate therapeutic anticoagulation (heparin or DOAC) at presentation and continue for ≥4 weeks post-cardioversion 1
• Some guidelines recommend TEE even for acute onset to exclude thrombus, particularly in higher-risk patients 2

For AF/Flutter Duration ≥48 Hours or Unknown Duration

Two acceptable pathways exist:

1. Delayed cardioversion approach:

   • Provide therapeutic oral anticoagulation for ≥3 weeks before cardioversion 1
   • DOACs are preferred over warfarin (INR 2.0-3.0) 1
   • Confirm adherence to DOACs or INR ≥2.0 for warfarin before proceeding 1

2. TEE-guided early cardioversion:

   • Perform TEE to exclude left atrial/appendage thrombus 1
   • If no thrombus present, proceed with cardioversion after 48 hours of therapeutic anticoagulation 3, 4
   • This approach allows earlier rhythm restoration while maintaining safety

Post-Cardioversion Anticoagulation

• Continue anticoagulation for minimum 4 weeks in all patients regardless of apparent sinus rhythm maintenance 1
• Long-term anticoagulation is mandatory for patients with thromboembolic risk factors (CHA₂DS₂-VASc score ≥1 in men, ≥2 in women), independent of rhythm status 1

Critical pitfall: Never perform early cardioversion without appropriate anticoagulation or TEE if AF duration exceeds 24 hours 1. The atrial mechanical stunning post-cardioversion creates thromboembolism risk even after successful rhythm conversion.

Energy Settings and Technical Approach

Waveform and Energy Selection

• Use biphasic waveform defibrillators - they achieve significantly higher success rates than monophasic (RR 1.71 for initial success, RR 1.10 for cumulative success) 5
• Initial energy: 200 J for biphasic waveforms 3, 5
• For monophasic defibrillators (if biphasic unavailable): start at 300-360 J 3
• Fixed high-energy strategy (≥200 J) is superior to escalating energy (RR 1.62 for initial success) 5
• Atrial flutter typically requires lower energy (50 J initial) compared to atrial fibrillation 4

Pad Positioning

• Anteroposterior position is recommended as the standard approach 3
• Anteroapical/anterolateral positioning shows no significant difference in success rates (RR 1.16, not statistically significant) 5
• Ensure wide pad separation to prevent current shunting along chest wall 4
• Use large electrode pads; avoid pediatric electrodes except in infants <1 year 4

Technical Optimization

• Apply manual pressure to pads during shock delivery - this significantly improves success (RR 2.19 for initial success, RR 1.19 for cumulative success) 5
• Use gel couplants with firm pressure to reduce transthoracic impedance 4
• Always synchronize shocks to R wave to avoid inducing ventricular fibrillation during the vulnerable period 4

Sedation Protocol

Provide adequate procedural sedation to achieve amnesia and prevent pain - not merely anxiolysis 4, 6:

• Propofol (administered by anesthesiologist or trained provider) provides rapid onset and short recovery 6
• Alternative: midazolam plus morphine (can be safely administered by trained electrophysiologists) 6
• Goal is complete amnesia - patients should not recall the shock 6
• Both sedation strategies are safe with no reported complications in comparative studies 6
• Midazolam/morphine combination is cost-effective when administered by trained non-anesthesiologists 6

Sedation pitfall: Inadequate sedation causes patient distress and recall of painful shock. Ensure sufficient depth before proceeding.

Post-Procedure Monitoring

Immediate Post-Cardioversion

• Monitor for return of atrial fibrillation (immediate recurrence occurs in some patients) 3
• Assess hemodynamic stability and rhythm on continuous telemetry
• Observe for complications including hypotension from sedation medications 7

Anticoagulation Continuation

• Verify anticoagulation is continued for minimum 4 weeks regardless of rhythm 1
• For patients with stroke risk factors, transition to long-term anticoagulation 1
• The atrial mechanical function remains impaired for weeks post-cardioversion despite electrical restoration of sinus rhythm

Follow-Up Assessment

• Emergency department cardioversion with same-day discharge is safe and effective for appropriately selected patients (97% success rate, high patient satisfaction, no complications in studies) 7
• Median length of stay can be as short as 4 hours for uncomplicated cases 7
• Arrange cardiology follow-up for rhythm assessment and long-term management planning
• Consider antiarrhythmic drugs or catheter ablation for recurrent episodes 1

Key consideration: The 2024 ESC guidelines 1 represent the most current and authoritative recommendations, emphasizing DOAC preference, mandatory post-cardioversion anticoagulation regardless of rhythm outcome, and the critical 3-week pre-cardioversion anticoagulation requirement for non-acute presentations.